What question did this study set out to answer?

To investigate the impact of CD8αMyD88 engineered T-cells on IL-2 sensitivity and TIL therapy efficacy.

November 25, 2025The Journal of Immunology

Enhanced IL-2 sensitivity for improved TIL therapy efficacy using CD8αMyD88 engineered T-cells 3978

View Full Paper

Ask AI

Bookmark

To investigate the impact of CD8αMyD88 engineered T-cells on IL-2 sensitivity and TIL therapy efficacy.
Utilized a B16-F10 melanoma mouse model.
Engineered CD8 T-cells with a synthetic co-receptor, CD8αMyD88.
Assessed T-cell expansion at various IL2 concentrations in healthy donors and TILs.
CM T-cells showed superior expansion potential across IL2 concentrations.
Enhanced IL2 sensitivity resulted in superior tumor regression.
In-vivo testing demonstrated enhanced antitumor efficacy with lower doses of IL2.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Engineered T-cells show improved tumor regression and reduced immune-related adverse events, indicating enhanced IL-2 sensitivity in adoptive cell transfer therapies.

Cite This Study

Cao et al. (2025) studied this question.

synapsesocial.com/papers/692502be87af00ed34ac215d https://doi.org/10.1093/jimmun/vkaf283.1715

View Full Paper

Ask AI

Bookmark

Implication

Engineered T-cells show improved tumor regression and reduced immune-related adverse events, indicating enhanced IL-2 sensitivity in adoptive cell transfer therapies.

Enhanced IL-2 sensitivity for improved TIL therapy efficacy using CD8αMyD88 engineered T-cells 3978

Key Points

Discussion

Implication

Cite This Study

Enhanced IL-2 sensitivity for improved TIL therapy efficacy using CD8αMyD88 engineered T-cells 3978

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider